Abundance Wealth Counselors Has $917,000 Position in Pfizer Inc. $PFE

Abundance Wealth Counselors grew its holdings in Pfizer Inc. (NYSE:PFE) by 21.3% during the 2nd quarter, HoldingsChannel reports. The firm owned 37,849 shares of the biopharmaceutical company’s stock after acquiring an additional 6,649 shares during the quarter. Abundance Wealth Counselors’ holdings in Pfizer were worth $917,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. GKV Capital Management Co. Inc. acquired a new stake in shares of Pfizer in the first quarter valued at about $27,000. Bayforest Capital Ltd acquired a new stake in shares of Pfizer in the first quarter valued at about $28,000. North Capital Inc. acquired a new stake in shares of Pfizer in the first quarter valued at about $28,000. WPG Advisers LLC acquired a new stake in Pfizer during the first quarter worth about $35,000. Finally, Horizon Financial Services LLC acquired a new stake in Pfizer during the first quarter worth about $35,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Down 0.5%

Shares of PFE opened at $27.08 on Friday. The stock has a market cap of $153.94 billion, a price-to-earnings ratio of 14.40, a P/E/G ratio of 0.88 and a beta of 0.55. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The company has a 50-day moving average price of $24.62 and a two-hundred day moving average price of $24.14.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter last year, the company earned $0.60 earnings per share. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of recent research reports. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Morgan Stanley lifted their target price on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 6th. Bank of America lifted their target price on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. UBS Group reissued a “neutral” rating and set a $28.00 target price on shares of Pfizer in a research report on Wednesday. Finally, Citigroup lifted their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $28.29.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.